← All trials
NCT05753033
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2023
- Primary completion
- Sep 6, 2023
- Completion date
- Sep 6, 2023
- First posted
- Mar 3, 2023
- Last posted
- Nov 22, 2023
- Enrollment
- 56
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU)Lead sponsor
- Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.